Literature DB >> 15052382

Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals.

Rinaldo Bellomo1, Shigehiko Uchino, Toshio Naka, Li Wan.   

Abstract

OBJECTIVE: To assess multicentre, randomised, controlled trials (MC-RCTs) of systemic inflammatory response syndrome (SIRS) and sepsis conducted in Japan, published in Japanese and not available to English-language medical databases.
DESIGN: Methodological review.
SUBJECTS: All Japanese RCTs relevant to SIRS and sepsis. INTERVENTION: Identification of manuscripts using a Japanese electronic library. Critical analysis of methodology and reporting quality using a modified Methodological Quality Assessment Score and the CONSORT group check list. MEASUREMENTS AND
RESULTS: Three MC-RCTs were identified. In the first, 147 patients with septic shock were randomised to methylprednisolone (1000 mg i.v.) or placebo. In the second, 221 patients were randomised to 0.20 mg/kg per h or 0.004 mg/kg per h of sivelestat for acute lung injury with SIRS. In the third, 504 patients were randomised to immunoglobulin (5 g for 3 days) or to a control group. The average methodological quality score was higher than that of equivalent Western trials. The reporting quality (CONSORT checklist) was comparable to Western studies published during the same period.
CONCLUSIONS: Despite sound methodology and quality, the information obtained from relatively large Japanese critical care trials is not widely available to English-speaking investigators and therefore might be ignored in meta-analyses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052382     DOI: 10.1007/s00134-004-2196-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  19 in total

Review 1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

Review 2.  Randomized, controlled clinical trials in sepsis: has methodological quality improved over time?

Authors:  Jürgen Graf; Gordon S Doig; Deborah J Cook; Jean-Louis Vincent; William J Sibbald
Journal:  Crit Care Med       Date:  2002-02       Impact factor: 7.598

Review 3.  Evidence-based medicine in the therapy of the acute respiratory distress syndrome.

Authors:  Rüdger Kopp; Ralf Kuhlen; Martin Max; Rolf Rossaint
Journal:  Intensive Care Med       Date:  2002-02-08       Impact factor: 17.440

Review 4.  Treatment of ARDS.

Authors:  R G Brower; L B Ware; Y Berthiaume; M A Matthay
Journal:  Chest       Date:  2001-10       Impact factor: 9.410

5.  Evidence-based medicine. A new approach to teaching the practice of medicine.

Authors: 
Journal:  JAMA       Date:  1992-11-04       Impact factor: 56.272

6.  An expanded definition of the adult respiratory distress syndrome.

Authors:  J F Murray; M A Matthay; J M Luce; M R Flick
Journal:  Am Rev Respir Dis       Date:  1988-09

Review 7.  Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis.

Authors:  D J Cook; D L Sackett; W O Spitzer
Journal:  J Clin Epidemiol       Date:  1995-01       Impact factor: 6.437

8.  Continuous versus intermittent renal replacement therapy: a meta-analysis.

Authors:  John A Kellum; Derek C Angus; John P Johnson; Martine Leblanc; Martin Griffin; Nagarajan Ramakrishnan; Walter T Linde-Zwirble
Journal:  Intensive Care Med       Date:  2001-12-04       Impact factor: 17.440

9.  Parenteral administration of different amounts of branch-chain amino acids in septic patients: clinical and metabolic aspects.

Authors:  A García-de-Lorenzo; C Ortíz-Leyba; M Planas; J C Montejo; R Núñez; F J Ordóñez; C Aragón; F J Jiménez
Journal:  Crit Care Med       Date:  1997-03       Impact factor: 7.598

10.  Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study.

Authors:  C D Spies; K Reinhart; I Witt; A Meier-Hellmann; L Hannemann; D L Bredle; W Schaffartzik
Journal:  Crit Care Med       Date:  1994-11       Impact factor: 7.598

View more
  1 in total

1.  A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Kazumi Togo; Takayuki Noguchi
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.